Logo-jrip

Read This Article

Article History

Submitted: 11 Aug 2021
Accepted: 04 Oct 2021
ePublished: 30 Oct 2021

  Google Scholar Profile

PubMed Profile

Share This Article!

Export Citation

EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

Cited By


doi: 10.34172/jrip.2022.31948
  Abstract View: 654

Case Report

Management of a newly diagnosed case of myeloma kidney in a recently COVID-19 recovered patient

Muthukaruppaiah Suganya 1 ORCID logo, Varadharajan Jayaprakash 1* ORCID logo, Vasudevan Manimoliyan Duraimavalavan 2, Mathew Gerry George 1 ORCID logo, Raghavan Padmanabhan 1, Sailapathy Sreedhar 1 ORCID logo

1 Department of Nephrology, SRM Medical College and Research Centre, Kattankulathur, Tamilnadu, India
2 Department of Medical Oncology, SRM Medical College and Research Centre, Kattankulathur, Tamilnadu, India
*Corresponding authors: Varadharajan Jayaprakash, Email: jayaprakash2k@gmail.com, jayaprav@srmist edu.in

Abstract

Multiple myeloma is a malignant monoclonal plasma cell disorder occurring predominantly in the elderly population. Outcomes of coronavirus disease 2019 (COVID-19) are worse in elderly, persons with comorbid conditions such as malignancy and patients who are on immunosuppressive therapy. Here we report a case, in which COVID-19 unravelled the diagnosis of multiple myeloma and myeloma cast nephropathy. Bortezomib-based two drug induction immunosuppression, was given during the peak of second wave of COVID-19, and it resulted in clinical improvement and partial remission of multiple myeloma.
Keywords: Multiple myeloma, Myeloma kidney, Cast nephropathy, Bortezomib

Implication for health policy/practice/research/medical education:

Guidelines for induction immunosuppression treatment of hematologic malignancies such as myeloma are not available for a recently recovered patient from COVID-19. Post-COVID status should not discourage clinicians from administering induction immunosuppression for treatment for multiple myeloma.

Please cite this paper as: Suganya M, Jayaprakash V, Duraimavalavan VM, George MG, Padmanabhan R, Sreedhar S. Management of a newly diagnosed case of myeloma kidney in a recently COVID-19 recovered patient. J Renal Inj Prev. 2022; 11(x): x-x. doi: 10.34172/jrip.2022.xx.

First Name
Last Name
Email Address
Comments
Security code


Abstract View: 655

Your browser does not support the canvas element.

PDF Download: 0

Your browser does not support the canvas element.